Phase 2 study of breakthrough vaccine against Toxic Shock Syndrome successfully completed
· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers
· Outcome is also a major step in the battle against MRSA infections
· Phase 3 trial preparation underway
· Staphylococcal-induced Toxic Shock Syndrome (TSS) is a serious and life-threatening condition affecting at risk patients, including those with compromised immunity and premenopausal women
· Methicillin-resistant Staphylococcus aureus (MRSA) is a constant threat to patients and a major financial burden for healthcare